Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2018-09-24 Director's Dealing
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
Disclosure of large shareholdings
Director's Dealing Classification · 98% confidence The document explicitly details a transaction where a company controlled by an executive (Kjetil Myrlid Aasen) purchased subscription rights in PCI Biotech Holding ASA's rights issue. It quantifies the resulting shareholding percentage (increasing from 4.96% to 7.86%) and the total holding including close associates. This content directly relates to reporting personal share transactions by company directors/executives and changes in significant share ownership, which aligns most closely with 'Director's Dealing' (DIRS) or 'Major Shareholding Notification' (MRQ). Since the notification is triggered by the executive's related party purchasing shares/rights, DIRS is the primary fit, although MRQ is also relevant due to the crossing of ownership thresholds. Given the focus on the executive's related party transaction, DIRS is the most specific classification.
2018-09-24 English
Disclosure of large shareholdings
Major Shareholding Notification Classification · 98% confidence The document explicitly discusses the purchase of subscription rights and the resulting change in shareholding percentage for an individual/controlled entity (Myrlid AS and Kjetil Myrlid Aasen) in PCI Biotech Holding ASA. The text details the new total holding (shares and subscription rights) and the resulting ownership percentage (e.g., increasing to 7.86%). This directly corresponds to the definition of 'Major Shareholding Notification' (MRQ), which covers changes in significant share ownership levels crossing thresholds.
2018-09-24 English
PCI Biotech: Mandatory notification regarding exercise and trade of subscription rights
Director's Dealing Classification · 98% confidence The document details transactions involving the subscription, exercise of rights, and sale of subscription rights by the CEO, CFO, and other directors/management of PCI Biotech Holding ASA. These transactions relate to the company's ongoing rights issue and result in changes to their personal shareholdings. This type of mandatory notification regarding share transactions by company directors and executives falls directly under the definition of Director's Dealing (DIRS). Although it involves a rights issue (related to CAP), the core content is the disclosure of insider trades.
2018-09-20 English
PCI Biotech: Mandatory notification regarding exercise and trade of subscription rights
Share Issue/Capital Change Classification · 99% confidence The document explicitly details transactions involving the exercise and trade of subscription rights by primary insiders (CEO, CFO, Board members) related to an ongoing rights issue. This type of mandatory notification concerning personal share transactions by directors and executives falls directly under the definition of Director's Dealing (DIRS). Although it involves capital structure changes (rights issue), the focus is on the insider trading disclosure aspect.
2018-09-20 English
PCI Biotech: Mandatory notification regarding exercise and trade of subscription rights
Share Issue/Capital Change Classification · 99% confidence The document explicitly details transactions involving subscription rights, share subscriptions, and the resulting changes in shareholdings for company directors (Chairman and Board Members). This type of mandatory notification concerning personal share transactions by executives and directors strongly aligns with the definition of Director's Dealing (DIRS). Although it involves a rights issue (related to CAP), the core content is the disclosure of insider trades resulting from that issue.
2018-09-19 English
Oslo Børs - Tegningsrettene i PCI Biotech Holding ASA vil bli notert / The subscription rights in PCI Biotech Holding ASA will be listed 19.09.2018
Share Issue/Capital Change Classification · 95% confidence The document announces the listing of subscription rights ('Tegningsrettene') for PCI Biotech Holding ASA, detailing the ticker, ISIN, issue price (NOK 30), subscription period, and listing period. This information pertains directly to a capital structure event involving the issuance of rights related to new shares. This aligns best with the 'Capital/Financing Update' category, which covers fundraising and capital structure changes. While it is a short announcement, the specific nature of the announcement (listing of rights) is more precise than a general RPA or RNS.
2018-09-19 Norwegian

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.